System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Krzysztof Selmaj is an expert in Neurology at University of Warmia and Mazury in Olsztyn (Poland). As of October 2026, ScienceLeadR ranks Krzysztof Selmaj in the top 1% of experts worldwide for Multiple Sclerosis and Autoimmune Diseases, and in the top 1% of experts in Poland for Leukoencephalopathies. Krzysztof Selmaj has authored 465 publications, the most recent in 2026, and is an investigator in 41 clinical trials, 3 of them ongoing. SLR score: 1,663 (community average: 125). How the SLR is computed.

LeadR Profile

Krzysztof Selmaj University of Warmia and Mazury in Olsztyn Poland
1 663 ScienceLeadR Reputation 1663

Unlock

Register Login
Network Map

Neurology

Subspecialties: Immunology - Internal Medicine - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1988 - 2026
Source: PubMed

University of Warmia and Mazury in Olsztyn

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 465

Citations

Citations: 35 515 1st author: 56 Last author: 105 Unique author: 11

Main journals

Neurology 167
Mult Scler 32
J Neuroimmunol 25
Mult Scler Relat Disord 17
Neurol Neurochir Pol 16

Best Journals

N Engl J Med 10
Lancet Neurol 6
Lancet 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Long-term comparative outcomes in relapse activity and disability progression among anti-CD20 therapies in relapsing multiple sclerosis: An unanchored matching-adjusted indirect comparison.
PMID 42832972 — sclerosis, multiple sclerosis, therapeutics		Mult Scler Relat Disord20260
Unique expression pattern of circulating exosomal miRNA correlates with CNS pathology.
PMID 42495628 — cells, multiple sclerosis, micrornas, pathology, recycling, exosomes, immune system diseases, immunity, brain injuries, traumatic		Front Immunol20260
Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.
PMID 42292352 — sclerosis, multiple sclerosis, antibodies, monoclonal, therapeutics, wounds and injuries		Front Immunol20260
Summary of Research: Cognition and Employment Status of People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-Year CLARIFY-MS Study.
PMID 42271112 — sclerosis, multiple sclerosis, tablets, employment, cladribine, research, cognition		Neurol Ther20260
Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study.
PMID 42223882 — sclerosis, multiple sclerosis, tablets, employment, cladribine, cognition		Neurol Ther20260

Clinical Studies 41

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 28
Phase 2 11
Phase 2/Phase 3 1
Phase 4 1

By status:

Completed 33
Active not recruiting 4
Terminated 3
Recruiting 1

By type:

Interventional 41

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 40

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Rollover Study to Evaluate the Long Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis
2023-505974-14-00 — sclerosis, multiple sclerosis, safety		Phase 3Active not recruiting2022
A Double blind Randomized Active controlled Parallel group Phase 1 3 study to Compare Efficacy Pharmacokinetics Pharmacodynamics and Safety of CT P53 and Ocrevus in Patients with Relapsing remitting Multiple Sclerosis
2022-501622-37-00 — sclerosis, multiple sclerosis, safety, genes, p53, multiple sclerosis, relapsing-remitting, pharmacokinetics		Phase 3Active not recruiting2024
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
2024-517529-26-00 — safety, polyneuropathies		Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS